Martha Hosford Skapof, MD
Hematology & Oncology · Newark, DENPI 1457301657
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 25.2% of the total. Reporting peaked in 2019 at $227 and has fallen 56.9% since, to $98 in 2025. That places this record below the midpoint for hematology & oncology clinicians in DE, where the typical reported total is $750.
Across 11 payments — averaging $45.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$125
- Pharmacyclics LLC, An Abbvie Company$100
- Takeda Pharmaceuticals U.S.A., Inc.$80
- Genentech, Inc.$53
- E.r. Squibb & Sons, L.L.C.$27
- Merck$25
- plus $87 from 5 others
What the payments were for
- Food & beverage$21744%
- Education$27956%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $80 |
| Genentech, Inc. | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Merck | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Seagen Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavalisse$125
How this compares
$497 in reported general payments places this provider in the 35th percentile of 26 hematology & oncology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 35 | $571,516 |
| Lenalidomide | 40 | $481,557 |
| PomalystPomalidomide | 17 | $421,431 |
| CabometyxCabozantinib S-Malate | 13 | $291,591 |
| PromactaEltrombopag Olamine | 15 | $196,703 |
| EliquisApixaban | 112 | $127,595 |
| TykerbLapatinib Ditosylate | 11 | $107,178 |
| XareltoRivaroxaban | 52 | $67,818 |
| OxycontinOxycodone Hcl | 13 | $11,221 |
| Anastrozole | 102 | $3,119 |
| Letrozole | 107 | $2,789 |
| Exemestane | 34 | $2,752 |
| Hydromorphone Hcl | 12 | $1,210 |
| Fentanyl | 23 | $1,171 |
| Ondansetron Hcl | 49 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $100 | $571,51635 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $27 | $421,43117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 26 hematology & oncology providers in Delaware.
Other hematology & oncology in Newark
- Dhaval ShahNewark$10K
- Jason PalopoliNewark$4K
- Jamal MislehNewark$2K
- Evan LapinskyNewark$2K
- Kathiresan SuppiahNewark$2K
- Nicole LaslettNewark$1K
- Sujung ParkNewark$1K
- Ramya VaradarajanNewark$901
- Palak ShahNewark$750
- Amy McGheeNewark$646
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.